US Oncology Research Announces Schedule of Presentations at the 2015 American Society of Hematology Annual Meeting and Exposition

December 01, 2015

Sixteen presentations on clinical research conducted by top US Oncology Research affiliated investigators will take place at ASH 2015

The Woodlands, Texas (December 1, 2015) — Nearly 20 leading investigators affiliated with US Oncology Research participated in sixteen studies that will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, a premier scientific event in malignant and non-malignant hematology. ASH will be held December 5-8 at the Orange County Convention Center in Orlando, Fla. Seven oral and nine poster presentations co-authored by US Oncology Research affiliated investigators cover topics such as Hodgkin’s lymphoma, refractory multiple myeloma and chronic myeloid leukemia.

“The clinicians affiliated with US Oncology Research are focused on developing breakthrough innovations that will help address the unmet medical needs of cancer patients throughout the country,” said Lisa Holland, vice president, US Oncology Research. “Their dedication and effort supporting clinical research programs, such as those presented during ASH, underscores the important role America’s community oncology centers play in the future of cancer research and care. We are proud to once again have notable and outstanding clinical research, conducted by our affiliated oncologists, presented during this year’s 57th ASH annual meeting.”

Christopher Yasenchak M.D., oncologist with Willamette Valley Cancer Institute and Research Center and the associate chair of the Hematology Research Program with US Oncology Research, will be discussing the results of two lymphoma studies:

"On behalf of our patients as well as investigators and research staff affiliated with US Oncology Research, I am honored to present the results of two important studies that address significant unmet medical needs in classical Hodgkin lymphoma and high risk diffuse large B cell lymphoma,” said Dr. Yasenchak. “By providing opportunities for enrollment in state-of-the-art clinical trials in the communities where our patients live, US Oncology Research is playing an instrumental role in the development of more effective, less toxic cancer therapies every day."

Also among the findings being presented by investigators affiliated with US Oncology Research is the Phase 2 PYRAMID open-label trial of Bortezomib in patients with large cell lymphoma. Results of the trial, co-authored by Dr. Kathryn Kolibaba of Compass Oncology and Dr. Nicholas Di Bella of Rocky Mountain Cancer Centers, will be featured as an oral presentation, titled “Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial,” on Monday, December 7, 2015 4:30 PM – 6:00 PM ET in Tangerine 3 (WF3-4) at the Orange County Convention Center.

In addition to the three above referenced oral presentations, there will be four other oral presentations and nine poster sessions during ASH that feature US Oncology Research clinical investigators. The full schedule of US Oncology Research affiliated data presentations, including location information, can be found here (PDF, 104 KB).

For more information or to interview a trial investigator, contact Claire Crye at 281-825-9927 or or Amina Colter at 646-258-4659 or

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves 60 research sites and 165 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled more than 61,000 patients in more than 1,400 trials since inception in 1992 and have played a role in more than 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information visit

Public Relations Contact